Eliav Barr, M.D., Senior Vice President, Infectious Diseases and Vaccines Global Clinical Development at Merck Research Laboratories (MRL) in West Point, PA USA. In this capacity, Dr. Barr leads the clinical research and strategic efforts to develop medicines to prevent or treat life-threatening Infectious Diseases, including Human Papillomavirus, Hepatitis C, HIV, Cytomegalovirus, childhood/adolescence infectious diseases, and hospital-acquired bacterial and fungal infections.
Dr. Barr joined Merck & Co., Inc. in 1995 and in 1998 became the head of the Human Papilloma Virus (HPV) vaccine clinical program. He developed and implemented the development strategy for the program, including all clinical studies and regulatory submissions. The program resulted in the first demonstration that prophylactic administration of a vaccine targeting HPV types 6, 11, 16, and 18 is highly effective in reducing cervical, vulvar, and vaginal cancer risk and genital wart rates caused by these types. The vaccine that was evaluated in these studies (GARDASIL®, Merck & Co., Inc.) has been licensed in over 100 countries.
Thereafter, Dr. Barr managed product development teams in Oncology and Infectious Diseases, and then became Therapeutic Area Head for Infectious Diseases in 2013. In 2016, Dr. Barr was appointed as Senior Vice President in charge of global clinical development of preventative/treatment approaches to Infectious Diseases at Merck.
After receiving his undergraduate degree from Penn State University, Dr. Barr went on to earn his medical degree from the Jefferson Medical College in 1986 (summa cum laude) and completed an Internal Medicine residency, a Cardiology Fellowship, at Johns Hopkins in 1990. He subsequently pursued post-doctoral training at the University of Michigan, and was on faculty at the University of Chicago prior to joining Merck.